Physician profile
Paris Davis
NPI 1235877911
$4,872.30
in general payments reported to CMS, 2019-2025
21 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,052 · 2024: $947 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,474 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,474.32 |
| Education | $397.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $816.76 | 2023-2025 | Tremfya |
| Abbvie INC. | $731.26 | 2023-2025 | |
| Incyte Corporation | $618.15 | 2023-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $520.32 | 2023-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $310.44 | 2024-2025 | Nemluvio, Aklief |
| Ucb, INC. | $287.90 | 2024-2025 | Bimzelx |
| Pfizer INC. | $249.04 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $206.13 | 2023-2024 | Dupixent |
| Genzyme Corporation | $188.37 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $183.31 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $170.00 | 2024-2025 | |
| Journey Medical Corporation | $124.99 | 2025 | |
| Organon LLC | $122.02 | 2025 | Vtama, Nexplanon |
| Lilly USA, LLC | $89.42 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $85.38 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $54.80 | 2025 | Klisyri |
| Revance Therapeutics, INC. | $34.98 | 2025 | Daxxify |
| Leo Pharma INC. | $24.60 | 2025 | Spevigo |
| Genentech USA, INC. | $23.89 | 2023 | Erivedge |
| Dermavant Sciences, INC. | $17.01 | 2024 | Vtama |
| Strata Skin Sciences, INC. | $13.53 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paris Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.